Search Immortality Topics:

Page 21234..1020..»


Category Archives: Biotechnology

Forbion participates in US financing rounds – European Biotechnology News

Forbion, the European life sciences venture capital firm from The Netherlands, announced its participation in oversubscribed Series B financing in Capstan Therapeutics Inc. and Engrail Therapeutics. Both companies are located in San Diego, USA.

Forbion is throwing a few million into the ring in order to participate in oversubscribed financing rounds in the USA. Both Series B financings have obviously generated a great deal of interest and both have exceeded their own targets. And both companies are based in San Diego, California (USA). And both times Forbion joined as a new investor.

Engrail Therapeutics announced the close of an oversubscribed $157m Series B financing round on 19th of March. The round was co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn Inc., Ysios Capital, Longwood Fund, Eight Roads Ventures, and existing founding investor Pivotal Life Sciences. Since its inception in 2019, the Company has raised over $220m. Engrail is a precision neuroscience company focused on the development of transformational therapies in anxiety disorders, depression, posttraumatic stress disorder, and rare neurodegenerative diseases.

With strong financial backing from highly sophisticated and dedicated life science investors, we are well positioned to deliver multiple value-creating milestones. Notably, we look forward to completing our ongoing ENX-102 phase 2 study in generalized anxiety disorder and advancing the rest of our pipeline into clinical development, said Vikram Sudarsan, Ph.D., president and CEO of Engrail Therapeutics. Jasper Bos, Ph.D. (Forbion) joined the board of directors at Engrail.

Only one day later at the same place, with some of the same actors, Forbion announced its participation as a new investor in the closing of a $175m oversubscribed Series B financing in Capstan Therapeutics, Inc.

The Series B financing was led by RA Capital Management, with additional participation from new investors Johnson and Johnson Innovation, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments. Capstans brings together some high-ranking corporate ventures of major pharmaceutical companies in existing investors Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly, Leaps by Bayer, Novartis Venture Fund, OrbiMed Advisors, Pfizer Ventures, Polaris Partners, and Vida Ventures who also participated in the round. Capstan is a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP). The Company also announced the appointment of Forbion General Partner Nanna Luneborg, PhD, MBA, to its Board of Directors. Commenting on her appointment to the Capstan BoardNanna Luneborg said, We are delighted to join the outstanding team and investor syndicate at Capstan Therapeutics. Capstan is pioneering in vivo CAR-T therapy, eliminating the need for ex vivo cell modification, and with the potential to create a scalable, off-the-shelf product to the benefit of patients across multiple different diseases.

Capstan marks the tenth investment from Forbions Growth Opportunities II Fund which raised 600m in 2023. However, the almost simultaneous large investments in the USA are not yet sufficient evidence of a general trend at Forbion to orientate its activities more transatlantically. A portion of the total amount from previous funds was always reserved for the USA.

See the rest here:
Forbion participates in US financing rounds - European Biotechnology News

Posted in Biotechnology | Comments Off on Forbion participates in US financing rounds – European Biotechnology News

Regulatory Status Review | Animal and Plant Health Inspection Service – USDA APHIS

Under the revised regulations, developers have the option of requesting a permit and/or a regulatory status review of a plant developed using genetic engineering that has not been previously evaluated and determined to be nonregulated. This process replaces the petition process in the preexisting regulations. When a developer requests a regulatory status review, APHIS evaluates whether the plant requires oversight based on the characteristics of the plant itself rather than on the use of a plant pest in its development. If a plant developed using genetic engineering is found to be unlikely to pose a plant pest risk, APHIS will not require regulation under 7 CFR part 340. If APHIS is unable to reach such a finding, it will regulate the plant and it would be allowed to move only under permit. Once APHIS determines that a plant is not regulated, subsequent transformation events using the same plant-trait-mechanism of action combination would not be regulated.

RSR evaluates plant pest risk based on:

RSR will include one or two steps, depending upon the plant.

STEP 1(APHIS will complete Step 1 in 180 days)

Evaluate the characteristics of the plant developed using genetic engineering relative to an appropriate comparator plant to identify whether a plausible pathway to increased plant pest risk exists and the corresponding factors of concern.

NOTE: A developer can request both a permit and that APHIS complete the second step in the process.

STEP 2(APHIS will complete its entire evaluation within 15 months)

Evaluate the identified factors of concern involving the plant developed using genetic engineering to determine the likelihood and consequence of the plausible increased plant pest risk.

View post:
Regulatory Status Review | Animal and Plant Health Inspection Service - USDA APHIS

Posted in Biotechnology | Comments Off on Regulatory Status Review | Animal and Plant Health Inspection Service – USDA APHIS

Gezeiten’s biotech skincare works in harmony with your circadian rhythm – Wallpaper*

Gezeiten is a new skincare brand that takes its name from the German word for the ebb and flow of the sea tides. It is a fitting name, not only because the German-born brand uses marine extracts and mineral-rich, sub-oceanic water concentrate to create its products. But also because they are tailored to work harmoniously with the bodys natural rhythms for optimal results.

(Image credit: Courtesy of Gezeiten)

The brand was founded by two families: husband and wife Michaela and Michael Hiltebrandt, who are both scientists and creative brother and sister duo Charles and Claire Zurheide Bals. Collectively, they were drawn together by a belief that the skincare market is oversaturated with products, few of which deliver the results they promise. So they joined forces in the hopes of hitting on the secret that other brands were missing. We are interested in exploring human origins and revisiting how our skin functions as an organism, says the team over email. And also where we are headed, as human kind. This is precisely what has really driven our scientific journey with Gezeiten.

(Image credit: Courtesy of Gezeiten)

The result is a range of five products: a day cream, a night cream, a protecting serum, a rejuvenating serum and a seven-day treatment set. Each is formulated with the brands patented Earth Marine CellTech Complex, which is designed to prevent skin ageing at a cellular level by replenishing the skin barrier, supporting the skins natural healing process, detoxifying and hydrating.

The brand worked with biotech and marine biology experts to ensure that the formulation works; but they also recognised that to create truly cutting-edge and effective skincare, they had to ensure the ingredients were delivered to the skin at the most opportune moments. To do that, they developed daytime and nighttime formulations with time release functions to support the skins specific needs during the daytime stress phase and the nighttime regeneration phase.

(Image credit: Courtesy of Gezeiten)

By incorporating chronobiology (the study of the bodys rhythms) into the formulations, Gezeiten ensures that the products work to fill in the gaps a demanding, urban life creates, particularly when it comes to our disrupted sleep cycles. A major problem of our modern lifestyle is a disturbed circadian rhythm, which leads to skin disorders such as hypersensitivity of the skin, inflammation, eczema, and ultimately premature skin ageing, say the Gezeiten team.

(Image credit: Courtesy of Gezeiten)

We are focusing on synchronising disrupted circadian rhythms to maintain overall skin health, they continue. Sleep is important, but so is the quality of sleep and the stress we are exposed to. Cortisol levels also harm the skin, as does our lifestyle. The world has changed so much over the thousands of years and the skin is still the same. It is the interplay of different components that determines the quality and health of the skin. We take them all into account in the development of our current and future products.

(Image credit: Courtesy of Gezeiten)

After a month of use, the skincare starts syncing with the skins natural 28-day regeneration cycle, with a noticeable reduction of fine lines, wrinkles, and hyperpigmentation, as well as an increase in moisture.

Receive our daily digest of inspiration, escapism and design stories from around the world direct to your inbox

Our approach has led us to look at skin from a 360-degree point of view, says Gezeiten. So observing how the body works, active ingredients, the latest technologies on the market, and taking sustainability into account at every step, we have created a skincare range, but also the blueprint of skincare for the new age.

gezeiten.com

Read the original post:
Gezeiten's biotech skincare works in harmony with your circadian rhythm - Wallpaper*

Posted in Biotechnology | Comments Off on Gezeiten’s biotech skincare works in harmony with your circadian rhythm – Wallpaper*

Biotech Stocks: The Top 5 To Watch As Shares Trend Down – Investor’s Business Daily

Access to this page has been denied because we believe you are using automation tools to browse the website.

This may happen as a result of the following:

Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.

Reference ID: #4b848313-f24e-11ee-a312-fe09a6f36d33

Read more from the original source:
Biotech Stocks: The Top 5 To Watch As Shares Trend Down - Investor's Business Daily

Posted in Biotechnology | Comments Off on Biotech Stocks: The Top 5 To Watch As Shares Trend Down – Investor’s Business Daily

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? – TradingView

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the First Trust NYSE Arca Biotechnology ETF FBT, a passively managed exchange traded fund launched on 06/19/2006.

While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency.

Sector ETFs also provide investors access to a broad group of companies in particular sectors that offer low risk and diversified exposure. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 5, placing it in top 31%.

Index Details

The fund is sponsored by First Trust Advisors. It has amassed assets over $1.18 billion, making it one of the larger ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. FBT seeks to match the performance of the NYSE Arca Biotechnology Index before fees and expenses.

The NYSE Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.

Costs

Expense ratios are an important factor in the return of an ETF and in the long term, cheaper funds can significantly outperform their more expensive counterparts, other things remaining the same.

Annual operating expenses for this ETF are 0.56%, making it on par with most peer products in the space.

Sector Exposure and Top Holdings

Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.

This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.

Looking at individual holdings, Grifols, S.a. (adr) GRFS accounts for about 4% of total assets, followed by Ultragenyx Pharmaceutical Inc. RARE and Iqvia Holdings Inc. IQV.

The top 10 holdings account for about 36.19% of total assets under management.

Performance and Risk

The ETF has lost about -2.71% and is up about 0.50% so far this year and in the past one year (as of 04/01/2024), respectively. FBT has traded between $132.50 and $160.46 during this last 52-week period.

The ETF has a beta of 0.67 and standard deviation of 21.95% for the trailing three-year period, making it a high risk choice in the space. With about 31 holdings, it has more concentrated exposure than peers.

Alternatives

First Trust NYSE Arca Biotechnology ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, FBT is a good option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.

SPDR S&P Biotech ETF XBI tracks S&P Biotechnology Select Industry Index and the iShares Biotechnology ETF IBB tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $7.45 billion in assets, iShares Biotechnology ETF has $7.64 billion. XBI has an expense ratio of 0.35% and IBB charges 0.45%.

Bottom Line

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.

Zacks Investment Research

Read more from the original source:
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - TradingView

Posted in Biotechnology | Comments Off on Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? – TradingView

Yantai Zhenghai Biotechnology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag – Simply Wall St

Key Financial Results

All figures shown in the chart above are for the trailing 12 month (TTM) period

Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) exceeded analyst estimates by 1.4%.

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 2.6% from a week ago.

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Yantai Zhenghai Biotechnology, and understanding this should be part of your investment process.

Find out whether Yantai Zhenghai Biotechnology is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Read more from the original source:
Yantai Zhenghai Biotechnology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Posted in Biotechnology | Comments Off on Yantai Zhenghai Biotechnology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag – Simply Wall St